NEW YORK, Jan. 19, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on PDLI, PGNX, PTIE, and QURE which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com revisits the Biotechnology sector, which harnesses biological processes
On Thursday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. recorded a trading volume of 1.15 million shares. The stock ended at $2.75, declining 1.79% from the last trading session. The Company's shares have gained 17.02% over the past year. The stock is trading slightly above its 200-day moving average by 0.97%. Furthermore, shares of PDL BioPharma, which acquires and manages companies, products, royalty agreements, and debt facilities in the biotech, pharmaceutical, and medical device industries in the US, Europe, and internationally, have a Relative Strength Index (RSI) of 41.55. Get the full research report on PDLI for free by clicking below at: www.wallstequities.com/registration/?symbol=PDLI
New York-based Progenics Pharmaceuticals Inc.'s stock finished yesterday's session 1.93% lower at $6.10 with a total trading volume of 599,942 shares. The Company's shares have gained 6.46% in the last month. The stock is trading above its 50-day moving average by 4.67%. Furthermore, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have an RSI of 51.29.
On January 02nd, 2018, Progenics Pharma announced that it has completed enrollment in its Phase-3 study of 1404, a PSMA-targeted small molecule SPECT/CT imaging agent that is designed to visualize prostate cancer. The Phase-3 study enrolled approximately 450 patients in the US and Canada with newly-diagnosed or low-grade prostate cancer, whose biopsy indicates a histopathologic Gleason grade of ? 3+4 severity and/or are candidates for active surveillance. The free technical report on PGNX can be accessed at: www.wallstequities.com/registration/?symbol=PGNX
On Thursday, shares in Austin, Texas-based Pain Therapeutics Inc. saw a decline of 1.52%, ending the day at $7.79. The stock recorded a trading volume of 173,975 shares. The Company's shares have surged 85.92% in the last month, 90.00% in the previous three months, and 91.87% over the past year. The stock is trading 71.87% and 83.74% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Pain Therapeutics, which develops drugs for treating nervous system in the US, have an RSI of 67.12.
On January 09th, 2018, Pain Therapeutics announced positive results from a human abuse potential study of its late-stage drug candidate, REMOXY. Study results indicate that in non-dependent, recreational opioid users, nasal administration of REMOXY resulted in significantly lower abuse potential compared to immediate-release (IR) oxycodone. All study subjects reported reduced 'Drug Liking,' 'Take Drug Again,' and 'Drug High' for REMOXY compared to oxycodone IR. Sign up for free on Wall St. Equities and claim the latest report on PTIE at: www.wallstequities.com/registration/?symbol=PTIE
Amsterdam, the Netherlands headquartered uniQure N.V.'s shares ended the day 0.99% lower at $18.00 with a total trading volume of 329,720 shares. The stock has gained 3.63% in the last month, 54.24% over the previous three months, and 212.50% over the past year. The Company's shares are trading 6.24% above their 50-day moving average and 78.87% above their 200-day moving average. Additionally, shares of uniQure, which engages in the discovery, development, and commercialization of gene therapies in the Netherlands, have an RSI of 49.99.
On January 04th, 2018, research firm Janney initiated a 'Buy' rating on the Company's stock, with a target price of $25 per share.
On January 08th, 2018, uniQure announced its near-term objectives, following a transformational year of achievement and corporate execution. Key business accomplishments during 2017 included the Company's alignment with regulatory authorities to advance AMT-061 into late-stage clinical development in hemophilia B, progress with its research pipeline including AMT-130 in Huntington's disease, further enhancement of the Company's manufacturing capabilities, and the strengthening of its financial position. See the free research coverage on QURE at: www.wallstequities.com/registration/?symbol=QURE
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-biotech-stocks----pdl-biopharma-progenics-pharma-pain-therapeutics-and-uniqure-300585161.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Take the quiz on Rabies and test your knowledge about this infection that can affect the brain ...
Pneumonitis usually refers to inflammation of lung tissue due to various non-infective causes such ...
Fremanezumab-vfrm is used as a preventive treatment for a migraine headache in adult patients. It ...View All